Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03639051 · ClinicalTrials.gov registry record · NA
Evaluation of the Safety and Efficacy of TLD in Patients with COPD
A NA study of COPD, sponsored by Nuvaira.
- Active
- Registry status
- NA
- Development phase
- 464
- Enrollment target
- 20
- Study locations
NCT03639051: Active NA study of COPD, sponsored by Nuvaira.
NCT03639051 is a NA study of COPD that is active but no longer recruiting, run by Nuvaira. The registered enrollment target is 464 participants, below the 2,413-participant average among 85 other COPD trials with a reported enrollment target (81% lower). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03639051, a NA study of COPD, is active but no longer recruiting, sponsored by Nuvaira.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 464 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to confirm the safety and efficacy of the Nuvaira Lung Denervation System (Nuvaira System) in the treatment of COPD.
Primary Outcome
A COPD exacerbation will be defined as a complex of respiratory events/symptoms (increase or new onset) of more than one of the following: cough, sputum, wheezing, dyspnea or chest tightness with at least one symptom lasting three days requiring treatment with antibiotics and/or systemic steroids (moderate exacerbation) and/or hospital admission (severe exacerbation).
Conditions Studied
Interventions
- DEVICE Targeted Lung Denervation (TLD)
- OTHER Optimal Medical Care
Study Locations (20)
California
- UC Davis - Sacramento
- Harbor UCLA - Torrance
Illinois
- University of Chicago - Chicago
- Suburban Lung Associates - Elk Grove Village
Michigan
- University of Michigan - Ann Arbor
- Spectrum Health Medical Group - Grand Rapids
North Carolina
- Duke University - Durham
- First Health of the Carolinas - Pinehurst
Pennsylvania
- Temple Lung Center - Philadelphia
- University of Pittsburgh Medical Center (UPMC) - Pittsburgh
Texas
- St. Davids HealthCare - Georgetown
- Houston Methodist Hospital - Houston
Alabama
- University of Alabama at Birmingham (UAB) Lung Health Center - Birmingham
Arizona
- HonorHealth - Phoenix
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 464 participants |
| Start Date | 2019-05-23 |
| Est. Completion | 2028-09 |
| Phase | NA |
What the registry record for NCT03639051 still lists
NCT03639051 is an interventional study that assigns participants to a tested intervention. The registered 464 participants enrollment target is mid-sized for trials with a published cap, below the 2,413-participant average among 85 other COPD trials with a reported enrollment target (81% lower).
The record links to 1 condition, with COPD appearing as the primary indexed condition, and to 2 interventions - of which Targeted Lung Denervation (TLD) is the first listed.
NCT03639051 names 20 study sites across 14 states, led by California, Illinois, Michigan.
Frequently Asked Questions
What is clinical trial NCT03639051 about?
NCT03639051 is a clinical study titled "Evaluation of the Safety and Efficacy of TLD in Patients with COPD". The purpose of this study is to confirm the safety and efficacy of the Nuvaira Lung Denervation System (Nuvaira System) in the treatment of COPD.
What is the current status of trial NCT03639051?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 464 participants. The study started on 2019-05-23. Estimated completion is 2028-09.
What conditions does trial NCT03639051 study?
This clinical trial studies the following conditions: COPD.
What interventions are being tested in trial NCT03639051?
The interventions under investigation include: Targeted Lung Denervation (TLD) (DEVICE), Optimal Medical Care (OTHER).
Who is sponsoring clinical trial NCT03639051?
This trial is sponsored by Nuvaira, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03639051 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for COPD
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03639051's enrollment target sits among peer trials
464 17th of 85 higher than 69 of 85 other COPD trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other COPD trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Impact of Positive Airway Pressure Therapy on Clinical Outcomes in Older Veterans With Chronic Obstructive Pulmonary Disease and Comorbid Obstructive Sleep Apnea (Overlap Syndrome)
RECRUITING · NA
-
Evaluating the Safety and Efficacy of dNerva Lung Denervation System in Patients With COPD
RECRUITING · NA
-
Home Hospital for Suddenly Ill Adults
RECRUITING · NA
-
The Reducing REVISITS Study: A Cluster RCT
RECRUITING · NA
-
The Effect of a Technology-Mediated Integrated Walking and Tai Chi Intervention on Physical Function in Veterans With COPD and Chronic Musculoskeletal Pain
RECRUITING · NA
-
Closed Loop Oxygen Control in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Nasal High Flow in the Hospital
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04787744 · 464 participants · Phase 2
Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer
- NCT04855656 · 464 participants · Phase 1
Study of Lunresertib Alone or in Combination With RP-3500 or Debio 0123 in Patients With Advanced Solid Tumors
- NCT06283927 · 464 participants
The RECSUR-study: Resection Versus Best Oncological Treatment for Recurrent Glioblastoma (ENCRAM 2302)
- NCT06444295 · 464 participants · NA
Testing the Impact of Thrive App Versions on Alcohol Use and Posttraumatic Stress After Recent Sexual Assault
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI